0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2023
Published Date: February 2023
|
Report Code: QYRE-Auto-2S13639
Home | Market Reports | Health| Vision Care
Global Gene Therapy for Age related Macular Degeneration Market Research Report 2023
BUY CHAPTERS

Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2023

Code: QYRE-Auto-2S13639
Report
February 2023
Pages:67
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Gene Therapy for Age-related Macular Degeneration Market

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
The global Gene Therapy for Age-related Macular Degeneration market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Age-related Macular Degeneration.
The Gene Therapy for Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gene Therapy for Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Key Segmentations

By Company

  • RetroSense Therapeutics
  • REGENXBIO
  • AGTC

Segment by Type

  • Subretinal
  • Intravitreal

Segment by Application

  • Monotherapy
  • Combination Therapy

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Gene Therapy for Age-related Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

Scope of Global Gene Therapy for Age-related Macular Degeneration Market Report

Report MetricDetails
Report NameGlobal Gene Therapy for Age-related Macular Degeneration Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Subretinal
1.2.3 Intravitreal
1.3 Market by Application
1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Monotherapy
1.3.3 Combination Therapy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2018-2029)
2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Region
2.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029)
2.3 Gene Therapy for Age-related Macular Degeneration Market Dynamics
2.3.1 Gene Therapy for Age-related Macular Degeneration Industry Trends
2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers
2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges
2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue
3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2018-2023)
3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio
3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2022
3.5 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Type
4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029)
5 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Application
5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
6.2 North America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)
6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)
7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023)
8.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)
9.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023)
10.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 RetroSense Therapeutics
11.1.1 RetroSense Therapeutics Company Detail
11.1.2 RetroSense Therapeutics Business Overview
11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction
11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
11.1.5 RetroSense Therapeutics Recent Development
11.2 REGENXBIO
11.2.1 REGENXBIO Company Detail
11.2.2 REGENXBIO Business Overview
11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction
11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
11.2.5 REGENXBIO Recent Development
11.3 AGTC
11.3.1 AGTC Company Detail
11.3.2 AGTC Business Overview
11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction
11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
11.3.5 AGTC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Subretinal
    Table 3. Key Players of Intravitreal
    Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million)
    Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2023)
    Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2024-2029)
    Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends
    Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers
    Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges
    Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints
    Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2018-2023) & (US$ Million)
    Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2018-2023)
    Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022)
    Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2022
    Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2018-2023)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
    Table 21. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2018-2023) & (US$ Million)
    Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2018-2023)
    Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2024-2029)
    Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2018-2023) & (US$ Million)
    Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2018-2023)
    Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2024-2029)
    Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)
    Table 33. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
    Table 34. Europe Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)
    Table 36. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million)
    Table 39. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)
    Table 42. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
    Table 43. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
    Table 46. RetroSense Therapeutics Company Detail
    Table 47. RetroSense Therapeutics Business Overview
    Table 48. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product
    Table 49. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)
    Table 50. RetroSense Therapeutics Recent Development
    Table 51. REGENXBIO Company Detail
    Table 52. REGENXBIO Business Overview
    Table 53. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product
    Table 54. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)
    Table 55. REGENXBIO Recent Development
    Table 56. AGTC Company Detail
    Table 57. AGTC Business Overview
    Table 58. AGTC Gene Therapy for Age-related Macular Degeneration Product
    Table 59. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million)
    Table 60. AGTC Recent Development
    Table 61. Research Programs/Design for This Report
    Table 62. Key Data Information from Secondary Sources
    Table 63. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2022 VS 2029
    Figure 3. Subretinal Features
    Figure 4. Intravitreal Features
    Figure 5. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 6. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2022 VS 2029
    Figure 7. Monotherapy Case Studies
    Figure 8. Combination Therapy Case Studies
    Figure 9. Gene Therapy for Age-related Macular Degeneration Report Years Considered
    Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region: 2022 VS 2029
    Figure 13. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2022
    Figure 14. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022)
    Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2022
    Figure 16. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 17. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)
    Figure 18. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 19. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 20. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)
    Figure 22. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2029)
    Figure 30. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)
    Figure 38. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029)
    Figure 42. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
    Figure 45. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
    Figure 46. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023)
    Figure 47. Bottom-up and Top-down Approaches for This Report
    Figure 48. Data Triangulation
    Figure 49. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Low Vision Electronic Visual Aids Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-28J9655
Sun Feb 11 00:00:00 UTC 2024

Add to Cart

Global Medical Privacy Curtains Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-19D16679
Mon Feb 05 00:00:00 UTC 2024

Add to Cart

Global Vision Testing System Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14G7393
Mon Feb 05 00:00:00 UTC 2024

Add to Cart

Global F-Theta Lenses Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14Y13390
Mon Feb 05 00:00:00 UTC 2024

Add to Cart